How I treat elderly patients with diffuse large B-cell lymphoma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Diffuse large B-cell lymphoma (DLBCL) treatment has significantly advanced, primarily due to the introduction of the anti-CD20 antibody, rituximab.
• Modern immunochemotherapy, exemplified by the rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, achieves cure rates exceeding 50% in elderly DLBCL patients.

Purpose of the Study:

• To review the current treatment landscape for diffuse large B-cell lymphoma, with a focus on elderly patients.
• To discuss challenges in treating DLBCL, including patient suitability for standard therapy, supportive care, and managing treatment failures.
• To highlight future directions in DLBCL therapy, emphasizing novel antibodies and small molecules.

Main Methods:

• Review of current literature and clinical practice guidelines for diffuse large B-cell lymphoma treatment.
• Analysis of the efficacy and challenges associated with rituximab-based immunochemotherapy (R-CHOP).
• Discussion of supportive care strategies and the potential role of radiotherapy.

Main Results:

• Rituximab combined with CHOP chemotherapy is the standard treatment, offering significant cure rates for elderly DLBCL patients.
• Elderly patients require careful evaluation for treatment suitability and robust supportive care, including anti-infectious prophylaxis and growth factor support.
• Optimizing rituximab dosage and schedule, alongside developing novel targeted agents, are key areas for future progress.

Conclusions:

• While R-CHOP has improved outcomes, challenges remain in treating frail patients and those who relapse.
• Further advancements in diffuse large B-cell lymphoma treatment are anticipated through novel immunotherapies and small molecule inhibitors targeting lymphoma cell survival pathways.
• Prospective clinical trials and sustained patient and physician commitment are crucial for realizing these future therapeutic gains.